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term variability; SD2, long-term variability; Smax, maximum total shortening; Te, expiratory 
duration; Ti, inspiratory duration; TNF-α, tumor necrosis factor alpha; Ucn2, Urocortin-2; Vmax, 
maximum shortening velocity; VE, minute ventilation; VE/VCO2, ventilatory equivalent for carbon 
dioxide; VE/VO2, ventilatory equivalent for oxygen; VCO2, carbon dioxide production; VO2, oxygen 
consumption; VT, tidal volume; Wmax, maximum mechanical work; WT, wild-type; xIL-6R, anti-IL-
6R; ½ RT, half relaxation time. 
 
Key points summary 
 Impaired ventilatory capacity and diaphragm muscle weakness are prominent features of 
Duchenne muscular dystrophy (DMD), with strong evidence of attendant systemic and 
muscle inflammation. 
 We performed a two-week intervention in young wild-type and mdx mice, consisting of either 
injection of saline or co-administration of a neutralizing interleukin-6 receptor antibody (xIL-
6R) and Urocortin-2 (Ucn2), a corticotrophin releasing factor receptor 2 agonist. We 
examined breathing and diaphragm muscle form and function. 
 Breathing and diaphragm muscle functional deficits are improved following xIL-6R and Ucn2 
co-treatment in mdx mice. The functional improvements were associated with a preservation 
of mdx diaphragm muscle myosin heavy chain IIx fibre complement. 
 The concentration of the pro-inflammatory cytokine interleukin-1β was reduced and the 
concentration of the anti-inflammatory cytokine interleukin-10 was increased in mdx 
diaphragm following drug co-treatment. 
 Our novel findings may have implications for the development of pharmacotherapies for the 
dystrophinopathies with relevance for respiratory muscle performance and breathing. 
 
Abstract 
The mdx mouse model of Duchenne muscular dystrophy shows evidence of hypoventilation and 
pronounced diaphragm dysfunction. Six-week-old male mdx (n=32) and wild-type (WT; n=32) mice 
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antibodies (xIL-6R; 0.2 mg/kg) and corticotrophin-releasing factor receptor 2 agonist (Urocortin-2; 30 
µg/kg), subcutaneously over 2 weeks. Breathing and diaphragm muscle contractile function (ex vivo) 
were examined. Diaphragm structure was assessed using histology and immunofluorescence. Muscle 
cytokine concentration was determined using a multiplex assay. Minute ventilation and diaphragm 
muscle peak force at 100 Hz were significantly depressed in mdx compared with WT. Drug treatment 
completely restored ventilation in mdx mice during normoxia and significantly increased mdx 
diaphragm force- and power-generating capacity. The number of centrally-nucleated muscle fibres 
and the areal density of infiltrates and collagen content were significantly increased in mdx 
diaphragm; all indices were unaffected by drug co-treatment. The abundance of myosin heavy chain 
(MyHC) type IIx fibres was significantly decreased in mdx diaphragm; drug co-treatment preserved 
MyHC type IIx complement in mdx muscle. Drug co-treatment increased the cross-sectional area of 
MyHC type I and IIx fibres in mdx diaphragm. The cytokines IL-1β, IL-6, KC/GRO and TNF-α were 
significantly increased in mdx diaphragm compared with WT. Drug co-treatment significantly 
decreased IL-1β and increased IL-10 in mdx diaphragm. Drug co-treatment had no significant effect 
on WT diaphragm muscle structure, cytokine concentrations or function. Recovery of breathing and 




DMD; mdx; interleukin-6; Urocortin-2; corticotrophin releasing factor; diaphragm muscle; breathing. 
 
1. Introduction 
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease wherein patients lack the 
structural protein dystrophin. In the absence of dystrophin, extensive skeletal muscle weakness, 
damage and fibre remodelling occurs (Blake et al., 2002). Weakness extends to the striated muscles of 
breathing, with patients displaying diaphragm muscle dysfunction (De Bruin et al., 1997; Khirani et 
al., 2014) with consequential respiratory disturbance (Smith et al., 1989; Khan & Heckmatt, 1994) 
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Similar to DMD, the mdx mouse model of DMD shows evidence of diaphragmatic dysfunction and 
impaired ventilation (Stedman et al., 1991; Coirault et al., 1999; Mosqueira et al., 2013; Burns et al., 
2015; Burns et al., 2017c). Skeletal muscle weakness due to dystrophin deficiency is further driven by 
pathological changes due to extensive muscle damage, including muscle fibre degeneration and 
necrosis, fibrosis, inflammation and adipose tissue deposition. Inflammation is a secondary feature of 
DMD due to muscle damage caused by the absence of dystrophin (Deconinck & Dan, 2007). 
Inflammatory cells infiltrate damaged muscles mounting an inflammatory response through activation 
of cytokines and recruitment of additional immune cells to the damaged muscle (De Paepe & De 
Bleecker, 2013).  
 
The expression of inflammatory cytokines is elevated in muscle biopsies and plasma samples from 
DMD patients and the mdx mouse model of DMD, some of which include tumor necrosis factor 
(TNFα), interleukin-1 (IL-1) and interleukin-6 (IL-6) (Chahbouni et al., 2010; Messina et al., 2011; 
Pelosi et al., 2015a). IL-6 is considered a myokine that can be released from damaged muscle in 
response to muscle injury and is pleiotropic in nature. IL-6 exerts its pro-inflammatory actions via its 
trans-signalling pathway, mediated by the soluble IL-6 receptor (IL-6R). Recent studies examining 
blockade of IL-6 signalling in mdx mice have shown functional improvements in skeletal and smooth 
muscle (Pelosi et al., 2015a; Manning et al., 2016, 2017). 
 
Muscle fibre loss occurs in DMD, with necrotic muscle fibres replaced by connective and adipose 
tissue. Signalling through the corticotrophin releasing factor receptor (CRFR) has been shown to 
modulate muscle mass. Activation of CRFR2 (expressed in skeletal muscle) in mice has been shown 
to increase muscle mass and prevent muscle mass and function loss in atrophying muscle (Hinkle et 
al., 2003a; Hinkle et al., 2003b; Hinkle et al., 2004). Similarly, the CRFR2 agonist Urocortin-2 
(Ucn2) has been demonstrated to increase muscle mass and force in mdx mice (Reutenauer-Patte et 
al., 2012; Manning et al., 2017). Moreover, Ucn2 has been shown to exert beneficial effects on 
cardiac function in healthy subjects and heart failure patients (Stirrat et al., 2016). 
 
A recent study has demonstrated that neutralization of the IL-6R (xIL-6R) and stimulation of CRFR2 
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diaphragm muscle functional capacity, with co-treatment proving more effective than either drug 
administered independently due to additive inotropic effects (Manning et al., 2017). Combined 
treatment with xIL-6R and Ucn2 restored diaphragm muscle functional deficits in mdx mice, 
evidenced by improved force, work and muscle shortening capacity (Manning et al., 2017). Similarly, 
a co-treatment of xIL-6R and Ucn2 completely recovered pharyngeal dilator (sternohyoid) muscle 
force and power loss in mdx mice (Burns et al., 2017b). Co-treatment preserved the myosin heavy 
chain (MyHC) fibre complement and reduced the number of centrally-nucleated fibres in sternohyoid 
muscle, suggesting a reduction in muscle fibre damage (Burns et al., 2017b). We sought to build 
considerably on this previous work, extending studies to breathing, diaphragm muscle physiology and 
structural composition, as well as diaphragm  cytokine profiles in young adult (8 weeks of age) wild-
type and mdx mice following saline or combined xIL-6R and Ucn2 drug treatment.  
 
We hypothesized that drug co-treatment would reduce inflammation and improve the quality of 
diaphragm muscle, preserving muscle fibre type distribution. We further hypothesized that co-
administration of xIL-6R antibodies and Ucn2 would improve diaphragm muscle force-generating 
capacity and ventilatory capacity in mdx.  
 
2. Methods 
2.1 Ethical approval 
Procedures on live animals were performed under licence in accordance with Irish and European 
directive 2010/63/EU following ethical approval by University College Cork (AEEC #2013/035). 
Experiments were carried out in accordance with guidelines laid down by University College Cork 
Animal Welfare Body, and conform to the principles and regulations described by Grundy (2015). 
 
2.2 Animals 
Male and female WT (C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmd
mdx
/J) mice were purchased 
from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME, USA) and were bred in our 
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humidity-controlled facility, operating on a 12 h light:12 h dark cycle with food and water available 
ad libitum. Six-week-old male WT and mdx mice received an interventional drug treatment consisting 
of a co-administration of xIL-6R (IL-6R neutralizing antibody; MR16-1 (Okazaki et al., 2002); 0.2 
mg/kg; Chugai Pharmaceuticals, Chuo, Tokyo, Japan) and Ucn2 (CRFR2 agonist; 30 μg/kg; U9507; 
Sigma Aldrich, Wicklow, Ireland) or saline (vehicle control; 0.9% w/v). MR16-1 stock was stored at -
80
o
C and Ucn2 stock was stored at -20
o
C. A working solution containing both MR16-1 (26.7µg/ml) 
and Ucn2 (4µg/ml) was made in sterile saline, distributed in aliquots and stored at -20
o
C until day of 
injection. The doses and treatment protocol were chosen based on previous studies by our research 
group (Manning et al., 2016; Manning et al., 2017). Drug treatment consisted of a total of six 
consecutive subcutaneous injections to the scruff of the neck, each on alternate days over the course 
of two weeks beginning at 6 weeks of age. Animals were injected with a 7.5 μl bolus per gram body 
mass. Male WT and mdx mice were assigned at random to saline or drug treatment, establishing the 
following four groups: WT + saline, WT + treatment, mdx + saline and mdx + treatment. Animals 
were anaesthetized with 5% isoflurane by inhalation in air and euthanized by cervical dislocation. A 
study of sternohyoid muscle form and function from these mice was published previously (Burns et 
al., 2017b).  
 
2.3 Respiratory measurements 
Whole body plethysmography was used to examine ventilation in unrestrained and unanaesthetized 
mice during quiet rest. Mice from all four groups were studied: WT + saline (n = 14), WT + treatment 
(n = 10), mdx + saline (n = 10) and mdx + treatment (n = 12). Mice were introduced into 
plethysmograph chambers (Model PLY4211; volume=0.6L, Buxco Research Systems, Wilmington, 
NC, USA) and allowed a 60-90 minute acclimation period until sufficiently settled, with room air 
passing through each chamber (1 L/min). Experimental protocol: Following acclimation, a 20-30 
minute baseline recording was performed in normoxia. This was followed by a 20 minute hypoxic 
challenge (FiO2 = 0.1; balance N2). Following a 60 minute recovery in normoxia, a 20-30 minute 
normoxic baseline was recorded. Following this period, ventilatory responses to hypercapnic 
challenge (5% CO2; balance O2) were assessed in mice from all four groups. Unfortunately, technical 
issues encountered in two groups (WT + treatment and mdx + treatment) relating to inaccurate pre-
calibrated gases necessitated exclusion of the complete data set, limiting comparisons to WT + saline 
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frequency (fR), tidal volume (VT), minute ventilation (VE), inspiratory duration (Ti) and expiratory 
duration (Te) were recorded on a breath-by breath basis for analysis offline. Data analysis: For the 
assessment of ventilatory parameters in normoxia, both normoxia bouts were pooled to generate one 
set of baseline (normoxia) data after confirming that there was no significant difference for ventilatory 
parameters between the two normoxic periods in order to provide a broader characterization of 
breathing over longer recording periods consistent with the approach in our recent study (Burns et al. 
2017c). For the hypoxic gas challenge, data during hypoxia are compared with the preceding baseline 
period and data are presented on a minute-by-minute basis thereafter. Peak ventilation during hypoxia 
was determined over a period of one minute during 1-3 minutes of exposure when peak responses 
were observed. VT and VE were normalized for body mass (g). To assess respiratory stability during 
normoxia, the breath-to-breath (BBn) and subsequent interval (BBn+1) of 200 consecutive breaths were 
analysed. Short-term variability (SD1) and long-term variability (SD2) were calculated for all four 
groups (Peng et al., 2011; Souza et al., 2015). 
 
2.4 Metabolism measurements 
O2 consumption (VO2) and CO2 production (VCO2) were measured in mice undergoing the whole-
body plethysmography protocol during normoxic baseline periods and during exposure to hypoxia. 
Airflow through the chamber was maintained at 1 L/min. Fractional concentrations of O2 and CO2 
were measured in air entering and exiting the plethysmograph (O2 and CO2 analyser; ADInstruments, 
Colorado Springs, CO, USA) as previously described (Burns et al., 2017c). Data analysis: 
Calculation of VO2 and VCO2 was performed as previously described (Haouzi et al., 2009; Burns et 
al., 2017c). For the 20 min hypoxic challenge, metabolic-related data are shown after 5 min of 
exposure to ensure steady-state responses and complete washout of chamber gas and are presented on 
a minute-by-minute basis thereafter. The plethysmograph chamber volume used in the current study 
was 0.6L and flow rate was 1L/min. We assume that washout was effective by 5 tau i.e. ~3 minutes. It 
is essential that metabolism is assessed in steady-state conditions with the chamber fully equilibrated 
and so for these reasons data are expressed only from the 5
th
 minute in hypoxic challenges. This is 
consistent with the approach taken in our recent study (Burns et al. 2017c) and by others in the field. 
Data during hypoxia exposure were compared with the preceding baseline (FiO2 = 0.21) so as to 
determine the ventilatory and metabolic response to challenge. VO2 and VCO2 were normalized for 








2.5 Tissue collection 
The distance from nose-to-anus and nose-to-tail was examined postmortem as an index of somatic 
growth. The diaphragm muscle was excised with rib and central tendon intact and placed in a tissue 
bath at room temperature containing continuously gassed hyperoxic (95% O2/ 5% CO2) Krebs 
solution (in mM: NaCl, 120; KCl, 5; Ca
2+
 gluconate, 2.5; MgSO4, 1.2; NaH2PO4, 1.2; NaHCO3, 25; 
and glucose, 11.5) and d-tubocurarine (25μM) prior to functional analysis. The following organs and 
muscles were weighed (wet weight): spleen, lung, whole heart, right heart ventricle, left heart 
ventricle, tibialis anterior, extensor digitorum longus and soleus. 
 
2.6 Muscle physiology 
2.6.1 Ex vivo muscle preparation 
One costal portion of the diaphragm was used immediately for functional analysis and the other 
portion was snap frozen in liquid nitrogen and stored at -80
o
C for subsequent molecular analysis. 
Longitudinally arranged bundles were prepared for assessment of contractile function. A single 
longitudinal strip (2 mm in diameter) for each animal was suspended vertically between two platinum 
plate electrodes. Rib was attached to a fixed hook at one end and the central tendon was attached to a 
dual-mode lever transducer system (Aurora Scientific Inc.; Aurora, ON, Canada) by non-elastic 
string. Muscle preparations were studied in a water-jacketed muscle bath, containing Krebs solution, 
maintained at 35
o
C gassed with 95% O2/ 5% CO2. Preparations were allowed a 5 min equilibration 
period. 
 
2.6.2 Isometric protocol 
Following equilibration, the optimum length (Lo) was determined by adjusting the position of the 
force transducer by use of a micro-positioner between intermittent twitch contractions. The Lo was 
taken as the muscle length associated with maximal isometric twitch force in response to single 
isometric twitch stimulation (supramaximal stimulation, 1ms duration). Once Lo was determined, the 
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Peak isometric twitch force, contraction time (CT; time to peak force) and half relaxation time (½ RT; 
time for peak force to decay by 50%) were determined. Next, an isometric tetanic contraction was 
elicited by stimulating muscle strips with supramaximal voltage at 100 Hz for 300 ms duration. Peak 
isometric tetanic force was determined at 100Hz (O'Halloran, 2006; Burns & O'Halloran, 2016). Data 
analysis: Force was calculated in N/cm
2
 of muscle bundle cross-sectional area (CSA). The CSA of 
each muscle strip was determined by dividing the muscle mass (weight in grams) by the product of 
muscle Lo (cm) and muscle density (assumed to be 1.06 g/cm
3
). Normalizing force to muscle bundle 
CSA accounted for potential differences between preparations in the size of the bundle, 
notwithstanding that the preparation of muscle strips for study was standardized. We deemed this 
approach to be more appropriate than representation of absolute forces, although the outcomes of our 
study proved similar whether absolute or normalized forces were compared between groups. 
However, we acknowledge that muscle density is likely to differ between WT and mdx due to 
collagen deposition in dystrophic muscle. The CT and ½ RT were measured as indices of isometric 
twitch kinetics. 
 
2.6.3 Isotonic protocol 
Following the isometric protocol, concentric contractions were elicited in incremental steps with 
varying load (0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 60%, 80, 100; % of force at 100Hz), 
with 30 s rest between each contraction. Muscle length returned to Lo following each contraction. 
Total shortening was determined as the maximum distance shortened during contraction. Shortening 
velocity was determined as the distance shortened during the initial 30 ms of shortening (Lewis et al., 
2015; Lewis et al., 2016). Mechanical work (force x total shortening) and power (force x shortening 
velocity) were determined at each step of the incremental load step test (Lewis et al., 2015; Williams 
et al., 2015; Burns & O'Halloran, 2016; O'Leary & O'Halloran, 2016). Data analysis: Data were 
plotted as the measured variable versus % load. Total muscle shortening was normalised to Lo and 
expressed in L/Lo. Similarly, shortening velocity was normalised to Lo and expressed in Lo/s. 
Maximum total shortening (Smax) and maximum shortening velocity (Vmax) were measured when 
both were maximal at 0% load. Mechanical work was measured in J/cm
2
. Mechanical power was 
expressed in W/cm
2
. Maximum mechanical work (Wmax) and power (Pmax) were also measured and 









2.7 Muscle immunohistochemistry and histology 
2.7.1 Tissue preparation 
A section of the diaphragm muscle was excised and mounted on a cube of liver, allowing for a 
transverse orientation of muscle fibres. The tissue was covered in optimum cutting temperature (OCT; 
VWR International, Dublin, Ireland) embedding medium and frozen in isopentane cooled in liquid 
nitrogen and stored at -80
o
C for subsequent structural analysis (n = 4-5 per group). A separate section 
of the muscle was placed in 4% paraformaldehyde overnight at 4
o
C before being transferred to 70% 
ethanol prior to tissue processing (Leica TP1020, Histokinet; Leica Biosystems, Dublin, Ireland) and 
paraffin embedding (Sakura Tissue-Tek TEC, Histolab Histowax embedding medium), for 
histological analysis (n = 4-5 per group).  
 
2.7.2 Myosin heavy chain fluorescence immunohistochemistry 
Serial transverse sections (10µm) were cryosectioned (Model CM30505; Leica Microsystems, 
Nussloch, Germany) at –22ºC and mounted on polylysine-coated glass slides (VWR International). 
Two slides per animal from 2 distinct regions containing a minimum of 4 sections per slide were 





Ltd., Peterborough, UK) was used to circumscribe each section on the slide, creating a well allowing 
for the containment of antibodies and to stop cross-reactivity of antibodies between muscle sections. 
Slides were immersed in phosphate-buffered saline (0.01M PBS; Sigma-Aldrich, Wicklow, Ireland) 
containing 1% bovine serum albumin (BSA; Sigma-Aldrich) for 15 mins, followed by three 5 min 
PBS rinses. This was followed by a 30 min wash in PBS containing 5% goat serum (Sigma-Aldrich). 
Before application of the primary mouse monoclonal antibodies (developed by S. Schiaffino and 
obtained from the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa, IA, 
USA), slides were subject to a further blocking step to enable the use of mouse monoclonal primary 
antibody staining on mouse tissue. Slides were incubated for 1 hour at room temperature with an 
unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (1:13; Jackson ImmunoResearch Labs, 
West Grove, PA, USA) diluted in PBS, followed by three 2 min washes in PBS. A triple-labelled 
approach was used to tag the 3 principal myosin isoforms using a cocktail of antibodies that targeted 
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section a double-labelled approach was employed using a cocktail which consisted of a rabbit anti-
laminin antibody (1:500, Sigma-Aldrich) and a pan-MyHC antibody for the indirect determination of 
pure MyHC IIx fibres, BF35 (1:50), labelling all MyHC isoforms but IIx, enabling visualization of IIx 
fibres by the absence of staining. The antibodies were diluted in PBS and 1% BSA and were 
incubated overnight at 4°C in a humidity chamber. Following this, slides were rinsed for three 5 min 
washes in PBS before application of the relevant secondary antibodies, diluted in PBS and 1% BSA. 
A cocktail of secondary antibodies was prepared containing AlexaFluor350-conjugated goat anti-
mouse IgG2b (1:500, Invitrogen, Biosciences Ltd, Dun Laoghaire, Ireland), Dylight594-conjugated 
goat anti-mouse IgG1 (1:500; Jackson ImmunoResearch) and AlexaFluor488-conjugated goat anti-
mouse IgM (1:250; Invitrogen), targeting MyHC I, IIa and IIb, respectively. For the double-labelled 
sections a Dylight594-conjugated goat anti-mouse IgG1 (1:500; Jackson) and FITC-conjugated anti-
rabbit secondary antibody (1:250; Sigma-Aldrich) were applied for 1 hour in the dark at room 
temperature. Slides were rinsed with PBS for three 5 min washes, cover slipped with polyvinyl 
alcohol (PVA) mounting medium with DABCO
®
 anti-fade (Sigma-Aldrich) before observation with a 
fluorescent microscope (Olympus BX51). Negative control experiments were run in parallel where 
the primary antibodies were omitted and the secondary antibodies were applied to ensure that tagging 
was specific. Slides for MyHC immunohistochemistry were processed in parallel across all 4 groups 
and confocal image acquisition was performed with standardized exposure settings. Data analysis: 
For MyHC fibre type analysis, muscle sections were viewed at x10 magnification and images 
captured using an Olympus BX51 microscope and an Olympus DP71 camera. Cell Sens™ (Olympus) 
was used to digitally capture the images. Analysis was carried out using image J software, where fibre 
type CSA and fibre type distribution (areal density) for each MyHC fibre type were determined 
(Burns et al., 2017b). For each animal, multiple sections throughout the muscle were viewed and 3-4 
images analysed per fibre type.  
 
2.7.3 Histological analysis 
Paraffin embedded diaphragm muscle samples were sectioned using a microtome (Leica RM2135). 
Serial cross-sections (5 μm thick) were collected throughout the muscle (mid-belly and distal regions) 
onto polylysine coated glass slides (VWR) and oven-dried (overnight at 37°C) for histological 
analysis. To examine putative inflammatory cell infiltration, and central nucleation of muscle fibres, 
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trichrome protocol was followed (Sigma-Aldrich). Slides were mounted using DPX mounting 
medium (Sigma-Aldrich, USA), air-dried and visualized on a bright field microscope (Olympus 
BX51) at x20 magnification. For H&E staining, slides were processed using muscle sections from all 
4 groups using the same reagents. Batches were processed in iterative fashion. Occasionally, it was 
necessary to re-run the histology with new sections but this always included a selection of slides from 
different experimental groups. Brightness was adjusted within each imaging session for optimal 
images. For Masson’s Trichrome staining, tissue sections were processed in batches ensuring 
equivalent incubation times across all 4 groups in parallel using the same reagents. Contrast and 
brightness was standardized as this was important for colour thresholding during image analysis. This 
was carefully and rigorously controlled. Data analysis: H&E stained sections were visualized at x20 
magnification. Six sections were examined across the muscle from the rostral, middle and caudal 
regions. Two randomly selected areas were captured per muscle section from non-overlapping areas 
for analysis. Muscle pathology was scored using ImageJ software. The number of myofibres 
displaying central nucleation was expressed as a percentage of the total number of myofibres per 
image. Putative inflammatory cell infiltration (the presence of cells in the extracellular matrix) was 
also scored and expressed as a percentage of the total area of muscle. Three sections, with two images 
captured per section, from the mid-portion of the muscle, were analysed per animal. Images were 
analysed using a colour balance threshold (ImageJ software), and the area of collagen was expressed 
as a percentage of the total area of muscle. 
 
2.7.4 Fluorescently-labelled collagen binding protein 
Additional collagen staining of the diaphragm muscle was carried out using a fluorescent collagen 
marker (CNA35-OG488), developed by (Krahn et al., 2006) and kindly gifted by the Department of 
Zoology, Trinity College Dublin. The CNA-35 probe is specific for type I and III collagen, found 
abundantly in skeletal muscle tissue. Following deparaffinisation, slides were prepared for a citrate 
buffer (pH 6) antigen retrieval step and subsequently stored in PBS (0.01M) prior to fluorescent 
staining. Slides were incubated over night at 4
◦
C with CNA35-OG488 (1:100 dilution in PBS). 
Following staining, sliders were washed with PBS, incubated with Hoescht stain (Sigma-Aldrich) to 
visualize cell nuclei and finally cover slipped with PVA-DABCO mounting medium before 
observation with a confocal microscope (Leica SP8). Slides for immunohistochemistry were 
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standardized exposure settings, especially important for quantification of the relative area of collagen. 
Data analysis: For CNA35-OG488 analysis, non-overlapping serial images (x20 magnification) were 
taken across a whole diaphragm muscle section. Images were analysed using a colour balance 
threshold (ImageJ software), and the area of collagen was expressed as a percentage of the total area 
of muscle. 
 
2.8 Molecular studies  
2.8.1 Tissue preparation 
Diaphragm samples stored at -80
o
C were removed and allowed to defrost at 4
o
C for 5 minutes. All 
procedures were performed at 4
o
C to prevent protein degradation. Samples were homogenized in a 
lysis buffer (RIPA) made up from 10X RIPA, deionized water, 200mM sodium fluoride (NAF), 
100mM phenylmethylsulfonylfluoride (PMSF), protease cocktail inhibitor 1 and phosphatase cocktail 
inhibitor 2. Following the homogenization process, the reactant mixtures were centrifuged (15,339 x 
g) at 4
o
C for 20 min and the supernatants were harvested. The total amount of protein for each tissue 
sample was determined using the Pierce Bicinchoninic Acid Assay (BCA assay; Thermo Fisher 
Scientific, Dublin, Ireland). Supernatants were stored at -80
o
C for subsequent use.  
 
2.8.2 Cytokines 
A multiplex cytokine assay (K15048G-1; Meso Scale Discovery, Rockville, MD) was used to 
examine cytokine concentrations in diaphragm muscle from all four groups (n = 8 per group). The 
assay was performed according to the manufacturer’s instructions using an extended incubation time 
to improve detection (the plate was incubated overnight at 4
o
C). Following incubation, the plate was 
read on a Quickplex SQ 120imager (Meso Scale Discovery). Values for each inflammatory mediator 
within each sample in each group (expressed at pg/ml) were above the lower limits of detection. 
 
2.9 Statistical analysis  
Data are expressed as scatter point box and whisker plots (median, 25-75 percentile, and scatter plot) 
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CA, USA). For muscle immunohistochemistry and histology, group means were generated from 
multiple images averaged per animal. All data were statistically compared by two-way ANOVA 
(genotype x treatment) with Bonferroni post hoc test. P < 0.05 was deemed to be statistically 
significant. We have not reported statistical outcomes for WT+treatment compared with 
mdx+treatment throughout the text as this was not a focus of the study. 
 
3. Results 
Body mass and organ measurements 
Table 1 compares body mass, body length, organ and muscle mass in WT and mdx mice treated with 
saline or xIL-6R and Ucn2 (treatment). Spleen mass was significantly increased in mdx + saline (P < 
0.0001; two-way ANOVA with Bonferroni) compared with WT + saline. Muscle mass was 
significantly increased for mdx + saline tibialis anterior (P < 0.0001) and soleus (P < 0.01) compared 
with WT + saline. Extensor digitorum longus from mdx mice was significantly heavier than WT (P = 
0.001 (genotype); two-way ANOVA). There was a significant difference in body mass (P < 0.0001 
(genotype); two-way ANOVA) between age-matched WT and mdx mice; mdx mice were heavier. 
Drug co-treatment had no effect on body mass (P = 0.411 (treatment); two-way ANOVA). Spleen and 
muscle mass were also unaffected by drug treatment. 
 
Baseline ventilation and metabolism 
Respiratory flow traces for WT and mdx mice following saline or drug co-treatment are shown in Fig. 
1A. Minute ventilation during normoxia was significantly lower in mdx + saline compared with WT + 
saline (Fig. 1B; P < 0.01; two-way ANOVA with Bonferroni). The reduction in normoxic ventilation 
was due to a significantly lower tidal volume in mdx + saline compared with WT + saline (Table 2; P 
< 0.05). Respiratory frequency was significantly greater in mdx mice (Table 2; P = 0.0047 (genotype); 
two-way ANOVA). Drug co-treatment in mdx mice significantly increased minute ventilation (Table 
2 and Fig. 1B; P < 0.001; two-way ANOVA with Bonferroni), due to a significant increase in tidal 
volume (Table 2. P < 0.05; two-way ANOVA with Bonferroni) and respiratory frequency (Table 2; P 
= 0.0018 (treatment); two-way ANOVA). There was no evidence of altered respiratory variability in 
mdx + saline mice compared with WT + saline, based on measures of breathing variability (SD1 and 








There was no difference in VO2 (Table 2; P = 0.4439 (genotype); two-way ANOVA) and VCO2 
(Table 2 and Figure 1C.; P = 0.8405) between WT and mdx. Drug co-treatment significantly 
decreased VO2 (Table 2) and VCO2 (Table 2 and Fig. 1C) in WT (P < 0.05 and P < 0.01; two-way 
ANOVA with Bonferroni; VO2 and VCO2, respectively) and mdx mice (P < 0.05 and P < 0.05). The 
ventilatory equivalent for O2 (VE/VO2) was significantly increased in WT (Table 2; P < 0.05) and mdx 
mice (P < 0.05) following drug co-treatment. Similarly, the ventilatory equivalent for CO2 (VE/VCO2) 
was significantly increased by drug co-treatment for both WT (Table 2 and Fig. 1D; P < 0.001) and 
mdx mice (Fig. 1D; P < 0.001). Drug co-treatment had a significant effect on the ratio of VCO2 to VO2 
(Table 2; P = 0.0344 (treatment); two-way ANOVA). 
 
Ventilatory responsiveness to hypoxia 
Respiratory flow traces for WT and mdx mice during hypoxia following saline or drug co-treatment 
are shown in Fig. 2A. Ventilation was significantly lower in mdx + saline compared with WT + saline 
when examined as maximum ventilation during hypoxic challenge (Fig. 2B; P < 0.0001). The peak 
ventilatory response to hypoxia (ΔVE) was lower in mdx + saline compared with WT + saline (Fig. 
2C; P < 0.001; two-way ANOVA with Bonferroni). Drug co-treatment significantly increased peak 
ventilation (Fig. 2B; P = 0.0006) for mdx + treatment compared with mdx + saline. However, the peak 
ventilatory response to hypoxia (ΔVE) was unchanged in mdx + treatment compared with mdx + saline 
(Fig. 2C; P > 0.05). By comparison, in WT mice, drug co-treatment had no significant effect on peak 
ventilation in response to hypoxia (Fig. 2B; P = 0.716). VE/VCO2 increased in response to hypoxia 
(Fig. 2D; P < 0.0001). Drug co-treatment significantly increased VE/VCO2 during hypoxia in WT (P = 
0.024) but not mdx mice (P = 0.268). Ventilation was significantly lower in mdx + saline compared 
with WT + saline during hypercapnic challenge (VE during hypercapnia was 4.0 ± 1.4 versus 2.4 ± 0.8 
ml/min/g, two-way ANOVA with Bonferroni post hoc test, P < 0.001 for WT + saline (n=8) versus 
mdx + saline (n=8)). The peak ventilatory response to hypercapnia (ΔVE) was lower in mdx + saline 
compared with WT + saline (delta VE was 2.9 ± 1.5 versus 1.4 ± 0.7 ml/min/g, unpaired Student’s t 
test, P = 0.21  for WT + saline (n=8) versus mdx + saline (n=8)). We were unable to compare the 
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Isometric force and twitch contractile kinetics 
Table 3 shows data for diaphragm muscle contractile kinetics (CT and ½ RT) from WT and mdx mice 
following saline or drug co-treatment. Diaphragm CT was significantly higher for mdx + saline (P < 
0.05; two-way ANOVA with Bonferroni) compared with WT + saline. Drug co-treatment had no 
significant effect on CT. There was no significant difference between WT and mdx for ½ RT. 
Representative original traces for diaphragm muscle twitch and tetanic contractions, and maximum 
unloaded shortening are shown in Fig. 3A-C. Diaphragm twitch force was significantly lower in mdx 
+ saline (Fig. 3D; P < 0.05) compared with WT + saline. Drug co-treatment had no significant effect 
on diaphragm twitch force (Fig. 3D; P = 0.1766 (treatment); two-way ANOVA). Diaphragm peak 
tetanic force at 100 Hz was significantly lower in mdx + saline (Fig. 3E; P < 0.001; two-way ANOVA 
with Bonferroni) compared with WT + saline. Post hoc analysis showed that drug treatment 
significantly increased tetanic force in mdx, but not WT diaphragm (Fig. 3E; P < 0.05). The outcomes 
were equivalent when absolute diaphragm force was compared between groups. 
 
Isotonic contractile parameters and kinetics 
Table 3 shows data for diaphragm muscle isotonic contractile parameters: Wmax, Pmax, Smax and 
Vmax. Diaphragm Wmax was significantly reduced in mdx + saline compared with WT + saline (P < 
0.05; two-way ANOVA with Bonferroni). There was no significant effect of drug co-treatment on 
Wmax (P = 0.0857 (treatment); two-way ANOVA). Pmax was significantly reduced in mdx + saline 
compared with WT + saline (P < 0.05; two-way ANOVA with Bonferroni). Drug treatment 
significantly increased Pmax (P = 0.0276 (treatment); two-way ANOVA); Pmax was increased by 
~130% in mdx diaphragm following drug treatment. There was no significant difference in Smax or 
Vmax between WT and mdx diaphragms. Statistical significance was not achieved for the effect of 
drug co-treatment on Wmax and Vmax in mdx diaphragm, perhaps due to insufficient statistical 
power, but sizeable effects were noted, which may have physiological relevance. Drug co-treatment 
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Isotonic load relationships 
Figure 3 (F-I) shows data for diaphragm muscle isotonic load relationships. Loading had a significant 
effect on work (Fig. 3F; P < 0.0001; two-way ANOVA), power (Fig. 3G; P < 0.0001), shortening 
(Fig. 3H; P < 0.0001) and shortening velocity (Fig. 3I; P < 0.0001). Diaphragm from mdx + saline 
had significantly reduced work (P < 0.0001), power (P < 0.0001), shortening (P < 0.0001) and 
shortening velocity (P = 0.0003) compared with WT + saline. Drug treatment increased mdx 
diaphragm work (P < 0.0001) and WT diaphragm work (P = 0.059). Following drug co-treatment, 
power production was significantly increased in WT (P = 0.009) and mdx diaphragm (P < 0.0001). 
Shortening (P = 0.0001) and shortening velocity (P < 0.0001) were also significantly increased for 
mdx diaphragm after drug co-treatment.  
 
Myosin heavy chain fibre-type distribution 
Figure 4 shows data for MyHC fibre distribution of diaphragm muscles. Representative 
immunofluorescence images of diaphragm fibre-type distribution are shown in Fig. 4A. The fibre type 
distribution of MyHC type I fibres did not vary significantly between the four groups (Fig. 4B). For 
mdx + saline, the abundance of MyHC type IIa fibres was significantly increased compared with WT 
+ saline (Fig. 4C; P < 0.001; two-way ANOVA with Bonferroni), whereas the abundance of MyHC 
type IIx fibres was significantly reduced in mdx + saline compared with WT + saline (Fig. 4D; P < 
0.001). The abundance of MyHC type IIb fibres was significantly reduced in mdx compared with WT 
diaphragm (Fig. 4E; P = 0.0079 (genotype); two-way ANOVA). Diaphragm fibre type changes were 
prevented or reversed by drug co-treatment in mdx with a significant decrease in type IIa fibres (P < 
0.001; two-way ANOVA with Bonferrroni) and a significant increase in type IIx fibres (P < 0.001) 
observed compared with mdx + saline.  
 
Fibre cross-sectional area  
Figure 4F shows data for CSA for all fibre types in all 4 groups. There was no significant difference 
in the CSA of MyHC type I, type IIa, type IIx or type IIb fibres in mdx diaphragm compared with 
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with Bonferroni) and MyHC type IIx fibre CSA (P < 0.05) in mdx mice only. Drug co-treatment had 
no effect on the CSA of MyHC type IIa or type IIb fibres in WT and mdx diaphragms.   
 
Central nucleation and putative inflammatory cell infiltration  
Figure 5 shows data for diaphragm muscle histology. Figure 5A-C shows representative 
histological images of diaphragm muscle transverse sections stained with Haematoxylin and 
Eosin (A), Masson’s trichrome (B) and CNA35-OG488 (C). The proportion of diaphragm 
muscle fibres with centrally located nuclei was significantly increased in mdx + saline (Fig 
5D; P < 0.001; two-way ANOVA with Bonferroni) compared with WT + saline. Drug co-
treatment had no significant effect on central nucleation (P = 0.414 (treatment); two-way 
ANOVA). The areal density of inflammatory cell infiltration was significantly increased in 
mdx + saline diaphragm compared with WT + saline (Fig. 5E; P < 0.001; two-way ANOVA 
with Bonferroni). Drug co-treatment had no significant effect on the relative area of putative 
immune cell infiltration (P = 0.3114 (treatment); two-way ANOVA). 
 
Collagen content 
The areal density of collagen labelled using Masson’s trichrome (type I collagen) staining 
was significantly increased in mdx + saline compared with WT + saline (Fig. 5F; P < 0.0001; 
two-way ANOVA with Bonferroni). Drug co-treatment had no significant effect on type I 
collagen content (P = 0.278 (treatment); two-way ANOVA). Type I and type III collagen co-
expression, labelled with the fluorescent CNA35-OG488 probe, was significantly increased 
in mdx diaphragm compared with WT (Fig. 5G; P = 0.0449 (genotype); two-way ANOVA). 
Drug co-treatment did not affect the expression of diaphragm type I and III collagen (P = 
0.99 (treatment); two-way ANOVA). 
 
Inflammatory mediators 
Figure 6 shows data for selective cytokine concentrations in diaphragm muscle from WT and mdx 
mice after saline administration or drug co-treatment. There was a significantly increased 
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0.001), IL-5 (Fig. 6D; P = 0.002), IL-6 (Fig. 6E; P =0.0003), KC/GRO (Fig. 6H; P < 0.0001) and 
TNF-α (Fig. 6J; P < 0.0001) in mdx diaphragm compared with WT. Post hoc analysis revealed that 
diaphragms from mdx + saline showed significantly increased expression of IL-1β (Fig. 6A; P < 
0.001; Bonferroni), IL-6 (Fig. 6E; P < 0.001), KC/GRO (Fig. 6H; P < 0.001) and TNF-α (Fig. 6J; P < 
0.001) compared with WT + saline. Two-way ANOVA revealed that drug co-treatment significantly 
decreased IL-1β (P = 0.005) and significantly increased IL-10 (P = 0.029). Post hoc analysis revealed 
that drug co-treatment significantly decreased the pro-inflammatory cytokine IL-1β (Fig. 6A. P < 
0.01; Bonferroni) and significantly increased the anti-inflammatory cytokine IL-10 (Fig. 6F; P < 0.05) 
in mdx diaphragm compared with mdx + saline. The expression of IL-4 (Fig. 6C), IL-12p70 (Fig. 6G) 
and IFN-γ (Fig. 6I) were unchanged in mdx diaphragm compared with WT, and the concentrations of 
each of these were unaffected by drug co-treatment. Fig. 6K shows a heat map summarising the fold-
change of cytokines relative to the WT + saline group.  
 
4. Discussion 
The key findings of the present study are: (i) drug co-treatment with xIL-6R and Ucn2 restored mdx 
diaphragm muscle fibre complement equivalent to WT; (ii) drug co-treatment improved diaphragm 
force-generating capacity and restored normoxic ventilation in mdx mice; (iii) drug co-treatment had 
no significant effect on central nucleation, inflammatory cell infiltration and collagen deposition in 
mdx diaphragm; and (iv) drug co-treatment decreased IL-1β concentration and increased IL-10 
concentration in mdx diaphragm. 
 
Striated muscle weakness is a devastating result of dystrophin deficiency and associated pathology in 
DMD. Respiratory muscle function is compromised and boys with DMD have reduced ventilatory 
capacity, which declines with age (De Bruin et al., 1997; Khirani et al., 2014). Diaphragm muscle 
weakness and likely impaired performance of the upper airway musculature translates to sleep 
disordered breathing including obstructive sleep apnoea and hypoventilation in many boys with DMD 
(Smith et al., 1989; Barbé et al., 1994). Cardiorespiratory failure is the leading cause of death in 
DMD, thus treatment strategies aimed at improving and prolonging adequate cardio-respiratory 
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Diaphragm muscle weakness is well described in mdx mice from a young age (Coirault et al., 2003). 
In the current study, diaphragm muscle from mdx + saline mice showed significantly reduced twitch 
force and increased contraction time compared with WT + saline. Similarly, peak tetanic force at 
100Hz and maximum work- and power-generating capacity were significantly reduced for mdx + 
saline diaphragm compared with WT + saline. These data confirm previous findings illustrating 
mechanical dysfunction in the mdx diaphragm (Stedman et al., 1991). We have previously reported 
depressed diaphragm force-generating capacity in mdx diaphragm at stimulation frequencies relevant 
to eupnoeic (basal) breathing (Burns et al., 2017c). Although the principal inspiratory muscle is 
compromised in DMD and mdx mice, few studies have comprehensively examined respiratory 
function and ventilatory capacity in mdx mice, both important measures to consider when examining 
the effects of novel therapeutic strategies in animal models of myopathic disease. 
 
In the current study, we assessed breathing in conscious unrestrained mice using whole-body 
plethysmography. Minute ventilation during normoxia was significantly reduced in mdx + saline 
compared with WT + saline mice, consistent with our recent reports (Burns et al., 2015; Burns et al., 
2017c). The observed reductions in ventilation were the result of significant reductions in tidal 
volume in mdx mice. Although minute ventilation was lower in mdx mice, there was no difference in 
whole-body metabolism (as measured by VCO2) between age-matched saline-treated WT and mdx 
mice, consistent with recent data (Burns et al., 2017c). Consequentially, VE/VCO2 was lower in mdx 
compared with WT (24±8 versus 18±5; mean±SD, WT versus mdx), although this was not deemed 
statistically significant by post hoc analysis. Despite evidence of impaired normoxic ventilation in the 
mdx model, there is no apparent evidence of inherent respiratory instability based on the analysis of 
variability of inspiratory and expiratory durations in young mdx mice.   
 
Ventilation was significantly blunted in mdx mice evidenced by decreased minute ventilation during 
hypoxic gas exposure. Drug co-treatment significantly increased hypoxic ventilation, consistent with 
recovery of mechanical deficits in mdx mice. Of note, the acute ventilatory response to hypoxia, 
measured as the absolute change in ventilation from baseline was blunted in mdx mice, a finding 
consistent with mdx carotid body hypoactivity (Burns et al., 2017c). Drug co-treatment did not reverse 
this effect suggesting that the sensory deficit is unrelated to IL-6-dependent and/or CRFR2-dependent 
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exposure revealing a hypoxic hyperventilation in WT and mdx mice. Drug co-treatment significantly 
increased VE/VCO2 during hypoxia in WT, but not in mdx mice. 
 
Murine diaphragm muscle expresses MyHC type I, IIa, IIx and IIb fibres (Sieck et al., 2012; Burns et 
al., 2017c). Diaphragm muscle weakness in mdx + saline diaphragm was associated with an alteration 
in the distribution of MyHC isoform composition, with mdx + saline diaphragm expressing fewer 
MyHC IIx fibres and more MyHC IIa fibres compared with WT + saline. MyHC type II fibres display 
an incremental increase in force production from IIa to IIx to IIb, respectively. Thus, a shift in MyHC 
composition from IIx to IIa in mdx diaphragm muscle fibres likely has functional implications, 
consistent with mdx diaphragm exhibiting lower force- and power-generating capacity ex vivo. Similar 
alterations in MyHC distribution have been reported in pharyngeal dilator muscles from mdx mice 
(Burns et al., 2017b) and are likely due to ongoing muscle fibre damage and repair processes 
preventing muscle fibre MyHC isoform maturation during muscle development. 
 
Mechanical dysfunction of striated muscle is coupled with extensive inflammation of the respiratory 
and non-respiratory musculature in DMD (Messina et al., 2011) and mdx mice (Barros Maranhão et 
al., 2015). Inflammation occurs due to muscle fibre damage as a result of dystrophin deficiency. 
Inflammatory cells are recruited to the damaged muscle to repair injured fibres. There is elevated 
expression of inflammatory cytokines in plasma and muscle biopsies from DMD boys (De Pasquale et 
al., 2012; Cruz-Guzmán et al., 2015) and mdx mice (Rufo et al., 2011). Chronic immune activation 
and attendant inflammation, observed in DMD, can have detrimental effects on normal physiological 
function. During the years of ambulation, plasma cytokine levels appear to be near maximal in DMD 
boys and begin to decline thereafter when patients become non-ambulatory (Cruz-Guzmán et al., 
2015), perhaps due to the disuse of the lower limb musculature. IL-6 is one of many cytokines 
reported to be elevated in DMD (Rufo et al., 2011; Cruz-Guzmán et al., 2015; Pelosi et al., 2015a) 
and is of particular relevance due to its role as a myokine and muscle signalling molecule. Plasma IL-
6 is known to increase in response to intense exercise and in pathological diseases such as Crohn’s 
disease and rheumatoid arthritis (Maggio et al., 2006). IL-6 binds to the IL-6R which signals via the 
Janus kinase/signal transducer activator of transcription (JAK/STAT) pathway. IL-6 can have 
divergent actions on skeletal muscle signalling such as promoting both muscle growth and wasting. 
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cases, IL-6 has been linked with hypertrophic muscle growth and paradoxically linked to muscle 
atrophy and wasting (Muñoz-Cánoves et al., 2013). These conflicting actions may relate to different 
concentration levels of IL-6 and acute versus persistent action of IL-6 signalling pathways.  
 
The pro-inflammatory cytokines IL-1β, IL-6, KC/GRO and TNF-α were significantly increased in 
mdx + saline diaphragm muscle compared with WT + saline, indicating a pro-inflammatory signature, 
consistent with previous reports in mdx muscle (Porter et al., 2002). This elevated expression of 
inflammatory cytokines was associated with a significant increase in the percent infiltration of 
putative inflammatory cells in mdx + saline diaphragm compared with WT + saline. The number of 
muscle fibres expressing central nuclei in mdx + saline diaphragm was also elevated compared with 
WT + saline, indicating muscle fibre repair and regeneration. Blockade of IL-6 signalling in mdx mice 
has been shown to improve the capacity for treadmill exercise (Pelosi et al., 2015a), to normalize 
function of gastrointestinal smooth muscle (Manning et al., 2016), and exert modest effects on 
improving diaphragm force (Manning et al., 2017). Conversely, overexpression of IL-6 in mdx mice 
promotes muscle necrosis and satellite cell exhaustion (Pelosi et al., 2015b). Blockade of IL-6 
signalling in dystrophin-/utrophin-deficient mice ameliorated skeletal muscle damage and promoted 
muscle regeneration in the limb, but no beneficial effects were observed for cardiac and respiratory 
muscle (Wada et al., 2017). 
 
Muscle wasting and proteolysis are pathophysiological features of myopathies such as DMD. 
Corticosteroids have been the treatment of choice for many years in DMD, notwithstanding their 
unwanted side effects (Ricotti et al., 2013). Therapies aimed at activating anabolic signalling in 
functional muscle fibres may act to improve muscle force in DMD and mdx mice. The urocortins 
which bind to the CRFRs are known to modulate muscle mass and anabolic signalling pathways in 
skeletal muscle (Hinkle et al., 2003a). Upon activation of CRFR2, there is an increase in adenylyl 
cyclase and cAMP formation (Reutenauer-Patte et al., 2012). Skeletal muscle is known to express 
CRFR2, and activation of CRFR2 decreased nerve damage and corticosteroid- and disuse-induced 
skeletal muscle mass and function loss in mice, and increased muscle mass in non-atrophying muscle 
(Hinkle et al., 2003b). The CRFR2 agonist, Ucn2, has been shown to improve diaphragm muscle 
force (Hinkle et al., 2007; Manning et al., 2017), increase muscle mass (Hall et al., 2007) and 








In the current study, we investigated the effects of IL-6R blockade (xIL-6R) and CRFR2 agonism 
(Ucn2) on ventilation and metabolism and diaphragm muscle structure, function and cytokine 
concentration. Blocking the action of IL-6 was performed using a neutralizing IL-6R monoclonal 
antibody (Okazaki et al., 2002). Intervention began at a relatively young age (six weeks) and was 
performed for a 2 week duration. Breathing and diaphragm muscle assessments were performed 
following treatment at eight weeks of age. Recent findings from our group have shown this treatment 
strategy to improve diaphragm force-generating capacity (Manning et al., 2017) and to restore 
pharyngeal dilator muscle force in mdx mice (Burns et al., 2017b). In the latter study, the observed 
improvements in mdx pharyngeal dilator muscle function was associated with significantly reduced 
central nucleation of sternohyoid muscle from mdx mice following drug co-treatment (Burns et al., 
2017a). 
 
Co-treatment of xIL-6R and Ucn2 significantly increased diaphragm specific force in mdx + treatment 
compared with saline-treated mdx (9±3 versus 16±3 N/cm
2
; mean±SD, mdx + saline versus mdx + 
treatment). For isotonic load relationships, drug co-treatment significantly increased diaphragm work, 
power, shortening and shortening velocity for mdx diaphragm. These findings confirm and extend 
previous data describing improved muscle force following administration of xIL-6R and Ucn2 in mdx 
diaphragm (Manning et al., 2017) and upper airway muscle (Burns et al., 2017b). Of interest, 
enhanced force-generating capacity in WT diaphragm was not observed following co-treatment with 
xIL-6R and Ucn2.  
 
Diaphragm muscle MyHC composition was significantly altered following xIL-6R and Ucn2 co-
treatment in mdx mice. Drug co-treatment significantly reduced MyHC type IIa and increased MyHC 
type IIx fibre distribution in mdx diaphragm compared with saline treated mdx mice. Improved mdx 
diaphragm force-generating capacity following drug co-treatment may be due to preservation of 
MyHC type IIx fibres. Drug co-treatment in WT mice had no effect on diaphragm fibre type 
distribution compared with saline-treated WT, consistent with no change in force-generating capacity 
in WT diaphragm. Progression of mdx diaphragm muscle fibres from MyHC IIa to IIx may be due, at 
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findings are consistent with previous observations in sternohyoid muscle from mdx mice following the 
same therapeutic intervention (Burns et al., 2017b). In addition to preservation of MyHC fibre type 
distribution, drug co-treatment promoted hypertrophy (increased CSA) of MyHC type I and IIx fibres 
in mdx diaphragm which likely translates to functional improvements, since muscle force-generating 
capacity is proportional to fibre cross-sectional area. The observed hypertrophy of MyHC type I and 
IIx fibres may be a result of altered anabolic signalling mediated by Ucn2 in mdx mice. Drug co-
treatment had no effect on muscle fibre central nucleation indicating there were no apparent 
improvements in muscle fibre damage and repair processes. Moreover, collagen content was also 
unaffected by drug co-treatment. These data suggest that functional improvements observed in the 
mdx diaphragm are not as a result of improvements in muscle damage and fibrosis, but are rather 
likely due to effects on healthy muscle fibres. Of interest however, if the beneficial effects of drug co-
treatment relate to a positive inotropic effect on healthy fibres in mdx muscle, it appears unique to 
mdx since drug co-treatment did not increase WT diaphragm force. 
 
Enhanced diaphragm functional capacity and altered MyHC isoform composition following drug co-
treatment in mdx mice, was associated with significantly increased tidal volume and minute 
ventilation during normoxia compared with saline-treated mdx. Both tidal volume and minute 
ventilation, which were decreased in mdx + saline compared to WT + saline, were restored to WT + 
saline values in mdx mice following co-treatment. Indices of metabolism, VO2 and VCO2 were 
significantly reduced by drug co-treatment in WT and mdx compared with saline controls. The 
ventilatory equivalents for O2 and CO2 were both significantly increased by drug treatment in WT and 
mdx compared with saline-treated controls. Drug co-treatment had no effect on the variability of 
breathing in WT and mdx mice showing no overt effects of xIL-6R and Ucn2 on respiratory stability. 
The mechanism of the hypometabolic effect of drug co-treatment is unclear and warrants attention in 
future studies. 
 
Interestingly, drug co-treatment significantly decreased IL-1β concentration in mdx diaphragm, with a 
concomitant increase in the concentration of the anti-inflammatory cytokine, IL-10. These data 
suggest modest improvements in the pro/anti-inflammatory cytokine balance in mdx diaphragm. 
There was no significant effect of drug co-treatment on the relative area of the putative inflammatory 
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concentration in mdx diaphragm muscle. Drug co-treatment in WT and mdx mice had no effect on 
body mass, indices of somatic growth and muscle and organ mass, demonstrating no apparent adverse 




We used the mdx mouse model in our studies and compared findings to a separate age-matched inbred 
colony (BL10), which served as control. This study design is consistent with the general approach in 
the mdx literature and consistent with recent reports (Terrill et al., 2016; Whitehead et al., 2016; 
Burns et al., 2017c; Pinniger et al., 2017). A breeding strategy to generate mixed littermates who 
differ only in the absence or presence of dystrophin (Bellinger et al., 2009) would represent a 
refinement of our approach and should be considered by researchers into the future. Such strategies 
are commonplace in studies of genetically modified mice and rats. It is possible that the mdx 
phenotype that we describe is exaggerated compared with WT BL10 mice, because of an inbred 
mutation in the WT mice associated with gain of function, or perhaps more likely that the WT values 
for at least some variables are also impaired in the inbred WT mice due to one or more mutations 
leading to loss of function, which would lead to an under-representation of the dystrophin-deficient 
mdx phenotype, and perhaps confounders in the comparisons between mdx and BL10. Arguing against 
this point however, values for BL10 diaphragm force in this study compare well with the published 
literature for other mouse strains, and this was confirmed by us in the present study by assessment of 
age-matched male C57/BL6 diaphragm force (peak force = 21±4 N/cm
2
, mean±SD, n=3), which was 
equivalent to peak diaphragm force in C57/BL10. Moreover, this is generally consistent with 
previously published data from our group using adult male C57/BL6 mice (O’Leary & O’Halloran 
2016; O’Leary et al., 2018). We have previously performed ventilatory measures in C57/BL6 mice 
(O’Leary & O’Halloran 2016; O’Leary et al., 2018) and these values are similar to BL10 data 
reported by us (Burns et al., 2017c; present study) and the wider literature in other strains. Cross-
breeding of mdx with C57/BL6 to generate mixed genotype litters has been described in mdx studies 
(Bellinger et al., 2009), but it is important to consider that BL6 mice may not be a suitable 
background strain for ventilatory studies in dystrophin-deficient mice since BL6 mice express 
intrinsic respiratory instability and central apneas (Strohl, 2003). The issue of potential genetic drift in 
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that we report herein, which compare well with the published literature. Moreover, the primary focus 
of our study was examination of the effect of drug intervention on mdx muscle strength, quality and 
breathing, which is independent of any concerns that might be expressed in respect of the most 
appropriate control group for our study.  
 
It is important to acknowledge that muscle injury in mdx dystrophic muscle triggers a cascade of 
degeneration, regeneration, inflammation, oxidative stress and progressive damage, as seen in human 
DMD, such that physiological and pathophysiological traits at different time points in the disease, and 
models of it, may be reflective of the underlying processes at play per se inasmuch as they are of 
dystrophin deficiency. We see no conflict in the fact that the mdx model expresses complex 
physiological and pathophysiological responses in muscle (and nervous control of muscle) triggered 
by dystrophin lack, which may be recapitulated by other stressors (e.g. oxidative stress). As is the case 
in DMD, the weakened muscle is a reflection of a devastating combination of aberrant factors such 
that the explicit impact of dystrophin lack per se cannot easily be determined. There are several other 
mouse models of muscular dystrophy, for example D2-mdx (Coley et al., 2016) and mdx4cv/mTRG2 
(Yucel et al., 2018), which purportedly better recapitulate the human dystrophinopathies at least for 
limb and cardiac muscle. However, whether this also applies to the respiratory muscles and their 
control is much less clear. There are very distinct differences in the pathology of diaphragm and limb 
muscles in mdx. Since there is a paucity of information on the control of breathing in mdx mice (and 
essentially all other models), there is no way yet to know how different models compare and whether 
one particular model is optimal for studies of diaphragm function and breathing. It is important to 
emphasize that diaphragm force loss is substantial even at 8 weeks of age in mdx providing a useful 
model for the interventional study that we performed. Nevertheless, we acknowledge the need to 
confirm our findings in other models of muscular dystrophy, particularly if our study is to have 
translational value to DMD.  
 
Ventilatory capacity in mdx mice was assessed by whole-body plethysmography in conscious animals, 
which provides an estimate of tidal volume with known limitations (Mortola & Frappell, 1998; Burns 
et al., 2017c). We employed hypoxic gas challenges to increase ventilation, but this provides only a 
modest ventilatory challenge, especially in mice, which adopt a hypometabolic strategy in response to 
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breathing, which revealed a clear deficit in mdx compared with WT, but again the activation of the 
diaphragm required to increase ventilation in response to chemostimulation is modest. As such, we 
did not assess the full range of ventilatory capacity (and deficit) in mdx mice and the efficacy of drug 
co-treatment in restoring physiological function associated with high levels of diaphragm and 
accessory muscle activation. Peak diaphragm force-generating capacity was determined in ex vivo 
preparations in this study. Assessment of respiratory muscle function in situ, such as measurements of 
transdiaphragmatic pressure (Greising et al., 2013) and assessment of peak inspiratory pressure-
generating capacity in mice across a range of ventilatory and non-ventilatory behaviours would be 
useful in characterizing the magnitude of the mechanical deficit in mdx mice at 8 weeks of age, and 
the efficacy or otherwise of drug co-treatment in the preservation of ventilatory capacity.  
 
We acknowledge that our intervention strategy was relatively short-lived and applied at one early time 
point in a murine model of a progressive disease. In the future, drug co-treatment for longer durations 
and at different stages of disease progression across various models of DMD are necessary to fully 
explore the capacity for this novel intervention to influence muscle quality and strength, including the 
potential for deleterious outcomes or side effects with long-term drug treatment. Moreover, whereas 
the restoration of diaphragm strength and ventilation was impressive in our study, we concede that 
drug intervention did not affect muscle necrosis and fibrosis, and did not reduce the area of immune 
cell infiltrate in muscle tissue, although the explicit cellular nature of the infiltrate was not explored in 
this study. As such, the improvements in muscle function appear to relate to actions on healthy fibres 
in mdx muscle, which has implications in the context of translation of this interventional strategy to 
DMD patients. 
 
Summary & Conclusion 
In summary, mdx mice have impaired ventilation, diaphragm muscle weakness and MyHC fibre-type 
immaturity at an early age. Co-treatment with xIL-6R antibodies and Ucn2 recovered mdx diaphragm 
force-generating capacity. Drug co-treatment preserved the MyHC fibre complement in mdx 
diaphragm and also promoted hypertrophy of MyHC type I and IIx fibres in mdx but not WT 
diaphragm. Preservation and hypertrophy of mdx diaphragm muscle MyHC type IIx fibres may be 
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of necrosis, fibrosis and immune cell infiltration in mdx diaphragm, suggesting actions on healthy 
fibres, although interestingly no inotropic effect of drug co-treatment was evident in WT muscle. 
Normoxic ventilation was recovered in mdx drug-treated mice, mediated by restoration of tidal 
volume. Combined drug treatment led to improvements in diaphragm MyHC composition and force-
generating capacity, associated with improved ventilatory capacity in young mdx mice. These findings 
have relevance to the development of interventional therapies for human dystrophinopathies. 
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Figure 1. Ventilation in conscious mice during normoxia 
A, representative respiratory flow traces during normoxia (21% O2) in wild-type (WT) and mdx mice 
following six subcutaneous injections with saline (S; 0.9% w/v) or treatment [T; neutralizing 
interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 
weeks. Inspiration downwards. B-D, minute ventilation (B), carbon dioxide production (C; VCO2) and 
ventilatory equivalent for carbon dioxide (D; VE/VCO2) for WT and mdx mice following saline or 
drug treatment. Values (B-D) are expressed as scatter point box and whisker plots (median, 25-75 
percentile and scatter plot). Data were statistically compared by two-way ANOVA with Bonferroni 
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Figure 2. Ventilatory responsiveness to hypoxia 
A, representative respiratory flow traces during hypoxia (10% O2) in wild-type (WT) and mdx mice 
following six subcutaneous injections with saline (S; 0.9% w/v) or treatment [T; neutralizing 
interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 
weeks. Inspiration downwards. B, Group data (mean ± SD) for minute ventilation during baseline and 
peak ventilation during hypoxia for WT and mdx mice following saline or drug treatment. Data were 
statistically compared by repeated measures two-way ANOVA. C, Group data for peak ventilatory 
responsiveness (ΔVE) to hypoxia for WT and mdx mice following saline or drug treatment. Values are 
expressed as scatter point box and whisker plots (median, 25-75 percentile and scatter plot). Data 
were statistically compared by two-way ANOVA with Bonferroni post hoc test. *P < 0.05; ***P < 
0.001. D, group data (mean ± SD) for ventilatory equivalent for carbon dioxide (VE/VCO2) during 
baseline and after 5-20 min of exposure to hypoxia for WT and mdx mice following saline or drug 









Figure 3. Diaphragm muscle function  
A-C, original traces of muscle twitch (A) and tetanic (B) contractions and maximum unloaded 
shortening (C) for diaphragm muscle from wild-type (WT) and mdx mice following six subcutaneous 
injections with saline (S; 0.9% w/v) or treatment [T; neutralizing interleukin-6 receptor antibodies 
(0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. D and E, group data for 
twitch (D) and tetanic (E) force in WT (n = 7-10) and mdx (n = 8) diaphragm muscle following saline 
or treatment. Peak tetanic force was measured following stimulation at 100Hz ex vivo. Values are 
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were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. *P < 0.05; 
***P < 0.001. F-I, group data (mean ± SD) for work-load (F), power-load (G), shortening-load (H) 
and velocity-load (I) relationships in WT (n = 7-10) and mdx (n = 8) diaphragm muscle following 
saline or drug treatment. Data were statistically compared by two-way ANOVA.  
 
Work: load, P < 0.0001; genotype, P <0.0001; WT treatment, P = 0.059; and mdx treatment, P < 
0.0001.  
Power: load, P < 0.0001; genotype, P < 0.0001; WT treatment, P = 0.009; and mdx treatment, P < 
0.0001.  
Shortening: load, P < 0.0001; genotype, P < 0.0001; WT treatment, P = 0.968; and mdx treatment, P 
= 0.0001.  
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Figure 4. Diaphragm muscle fibre distribution and cross-sectional area (CSA) 
A, Representative immunofluorescence images of diaphragm muscle fibre-type distribution 
(A), showing type I (blue), type IIa (red), type IIx (untagged, appearing black) and type IIb 
fibres (green) for WT + saline (WT-S; top left), mdx + saline (mdx-S; top right), WT + 
treatment (WT-T; bottom left) and mdx + treatment (mdx-T; bottom right). Scale bars = 200 
µm. B-E, group data showing fibre distribution of type I (B), type IIa (C), type IIx (D) and 
type IIb fibres (E) in WT and mdx saline treated mice, and WT drug-treated and mdx drug-
treated mice (n=5) per group.  Mice received six sub-cutaneous injections of saline (0.9% 
w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 
(30 μg/kg); co-administered] over two weeks. Values are expressed as scatter point box and 
whisker plots (median, 25-75 percentile and scatter plot). Data were statistically compared by 
two-way ANOVA followed by Bonferroni post hoc test. ***P < 0.001. F, Group data (mean 
± SD) showing mean CSAs of diaphragm muscle fibre type I, type IIa, type IIx and type IIb. 
Data were statistically analysed by two-way ANOVA with Bonferroni post hoc test. *P < 
0.01. 
Type I: Genotype, P = 0.908; treatment, P = 0.036; interaction, P = 0.009.  
Type IIa: Genotype, P = 0.839; treatment, P = 0.291; interaction, P = 0.27.  
Type IIx: Genotype, P = 0.276; treatment, P = 0.005; interaction, P =0.106. 
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Figure 5. Diaphragm muscle histology 
A-C, Representative histological images of diaphragm muscle transverse sections stained 
with Haematoxylin and Eosin (A), Masson’s trichrome (B; type I collagen) and CNA35-
OG488 (C; type I and III collagen) in WT + saline (WT-S; first column), mdx + saline (mdx-
S; second column), WT + treatment (WT-T; third column) and mdx + treatment (mdx-T; 
fourth column) groups. Scale bars represent 100 µm. Peripherally located nuclei are apparent 
in WT saline and WT drug-treated images. In comparison, mdx mice (saline and drug-treated) 
displayed an increased incidence of centrally located nuclei. Inflammatory cell infiltration is 
not apparent in WT saline and WT drug-treated groups. The mdx muscle (saline and 
treatment) displayed inflammatory cell infiltration, highlighted with black arrows. D and E, 
group data showing the percentage of central nucleation (D) and percentage of infiltration of 
inflammatory cells (E) in diaphragm muscle from saline-treated WT (n = 5) and saline-
treated mdx mice (n = 4), and WT (n = 5) and mdx (n = 5) mice treated with neutralizing 
interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 µg/kg), co-administered as 
six sub-cutaneous injections over 2 weeks. F and G, group data showing percentage of type I 
collagen content (C) and type I and III collagen content (D) in diaphragm muscle from saline-
treated WT and saline-treated mdx mice, and WT and mdx mice (n = 4-5 per group) treated 
with neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 µg/kg) co-
administered as six sub-cutaneous injections over 2 weeks. Values are expressed as scatter 
point box and whisker plots (median, 25-75 percentile and scatter plot). Data were 
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Figure 6. Cytokine concentrations in diaphragm muscle. 
A-J, Group data (mean ± S.D) for selective cytokine concentrations in diaphragm muscle. Cytokines 
include interleukin-1β (A; IL-1β), interleukin-2 (B; IL-2), interleukin-4 (C; IL-4), interleukin-5 (D; 
IL-5), interleukin-6 (E; IL-6), interleukin-10 (F; IL-10); interleukin-12 (F; IL-12p70), (G; KC/GRO), 
interferon-γ (F; IFN- γ) and tumour necrosis factor-α (TNF-α) in diaphragm muscle from wild-type 
(WT) and mdx mice (n = 8 per group) injected subcutaneously with saline (S; 0.9% w/v) or drug 
treatment [T; neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); 
co-administered] over 2 weeks. K, Heat map illustrating fold-change in cytokine concentration 
relative to the WT + saline group. Red represents an increase in concentration. Data were statistically 


















Table 1. Body mass, somatic growth, organ and muscle mass 
Definition of abbreviations: N-A, distance from nose to anus; N-T, distance from nose to tip of tail; 
RV, right heart ventricle; LV, left heart ventricle; TA, tibialis anterior; EDL, extensor digitorum 
longus; sol, soleus; WT, wild-type. WT (n = 7-10) and mdx (n = 6-10) mice were injected 
subcutaneously with saline (0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies 
(0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. Data are shown as mean ± SD 
and were statistically compared using two-way ANOVA with Bonferroni post hoc test. *mdx saline 
significantly different from corresponding WT saline values, P < 0.05. 
 WT mdx  
 Saline  
(n = 10) 
Treatment 
(n = 7) 
Saline 
(n = 10) 
Treatment  




21.0 ± 1.3 21.6 ± 0.8 24.4 ± 1.7* 24.7 ± 1.6 Genotype: P < 0.0001; Treatment: P = 0.411; Interaction: 
P = 0.7638 
N-A (cm) 9.1 ± 0.2 9.2 ± 0.3 9.4 ± 0.2 9.1 ± 0.3 Genotype: P = 0.2576; Treatment: P = 0.2576; 
Interaction: P = 0.0121 
N-T (cm) 16.5 ± 0.3 16.8 ± 0.4 16.6 ± 0.3 16.8 ± 0.4 Genotype: P = 0.4746; Treatment: P = 0.038; Interaction: 
P = 0.549 




Genotype: P < 0.0001 ; Treatment: P = 0.6693; 







121.8 ± 9.0 124.0 ± 9.4 Genotype: P = 0.2576; Treatment: P = 0.1966; 
Interaction: P = 0.0556 




Genotype: P = 0.0167; Treatment: P = 0.7295; 
Interaction: P = 0.1112 
RV (mg) 25.8 ± 5.3 30.9 ± 3.5 31.5 ± 5.3 31.7 ± 6.8 Genotype: P = 0.1073; Treatment: P = 0.1821; 
Interaction: P = 0.2172 
LV (mg) 77.4 ± 7.6 68.5 ± 7.1 74.5 ± 7.1 78.5 ± 8.4 Genotype: P = 0.2028; Treatment: P = 0.3757; 
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RV:LV 0.34 ± 0.09 0.46 ± 0.09 0.42 ± 0.07 0.41 ± 0.09 Genotype: P = 0.5691; Treatment: P = 0.105; Interaction: 
P = 0.0354 
TA (mg) 34.7 ± 2.5 35.7 ± 1.5 58.4 ± 3.4* 70.0 ± 4.8 Genotype: P < 0.0001; Treatment: P = 0.1363; 
Interaction: P = 0.5224 
EDL (mg) 7.6 ± 2.2 6.2 ± 1.5 9.1 ± 1.8 9.2 ± 0.6 Genotype: P = 0.001; Treatment: P = 0.2852; Interaction: 
P = 0.266 
Sol (mg) 5.9 ± 1.3 6.0 ± 1.2 8.5 ± 1.7* 8.7 ± 1.9 Genotype: P < 0.0001; Treatment: P = 0.7927; 
Interaction: P = 0.9906 
 
Table 2. Baseline ventilation and metabolic measurements 
Definition of abbreviations: fR, breathing frequency; VT, tidal volume; VE, minute ventilation; VO2, 
oxygen consumption; VCO2, carbon dioxide production; VE/VO2, ventilatory equivalent for oxygen; 
VE/VCO2, ventilatory equivalent for carbon dioxide; VCO2/VO2, respiratory exchange ratio; Ti, 
inspiratory duration; Te, expiratory duration; SD1, short-term variability; SD2, long-term variability; 
WT, wild-type. WT (n = 10-14) and mdx (n = 10-12) mice were injected subcutaneously with saline 
(0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 
(30 μg/kg); co-administered] over 2 weeks. Data are shown as mean ± SD and were statistically 
compared using two-way ANOVA with Bonferroni post hoc test. 
ǂ
WT treatment significantly 
different from corresponding WT saline values, P < 0.05; *mdx saline significantly different from 
corresponding WT saline values, P < 0.05; 
#
mdx treatment significantly different from corresponding 
mdx saline values, P < 0.05.  
 WT mdx  
 Saline  
(n = 14) 
Treatment 
(n = 10) 
Saline 
(n = 10) 
Treatment  
(n = 12) 
Two-way ANOVA 
fR (bpm) 165.0 ± 11.2 177.7 ± 11.9
ǂ 176.4 ± 15.7 189.0 ± 12.7 Genotype: P = 0.0047; Treatment: P = 0.0018; 
Interaction: P = 0.977 
VT (ml/g) 0.0074 ± 
0.001 
0.0076 ± 0.001 0.0053 ± 
0.001* 
0.0071 ± 0.001# Genotype: P < 0.0001; Treatment: P = 0.0016; 
Interaction: P = 0.017 
VE (ml/g/min) 1.19 ± 0.17 1.32 ± 0.13 0.92 ± 0.19* 1.31 ± 0.21
# Genotype: P = 0.0103; Treatment: P < 0.0001; 
Interaction: P = 0.0166 
VO2 
(ml/g/min) 
0.065 ± 0.02 0.037 ± 0.01ǂ 0.068 ± 0.02 0.043 ± 0.02# Genotype: P = 0.4439; Treatment: P < 0.0001; 









0.054 ± 0.02 0.036 ± 0.01ǂ 0.052 ± 0.01 0.038 ± 0.01# Genotype: P = 0.8405 ; Treatment: P < 0.0001; 
Interaction: P = 0.6089 
VE/VO2 21.9 ± 11.7 38.3 ± 10.6
ǂ 14.6 ± 5.1 35.5 ± 14.3# Genotype: P = 0.1344; Treatment: P < 0.0001; 
Interaction: P = 0.5089 
VE/VCO2 23.9 ± 8.0 39.1 ± 18.2
ǂ 18.2 ± 4.6 36.7 ± 9.3# Genotype: P = 0.1228 ; Treatment: P < 0.0001; 
Interaction: P = 0.5234 
VCO2/VO2 0.85 ± 0.2 1.03 ± 0.3 0.80 ± 0.2 0.97 ± 0.3 Genotype: P = 0.4647; Treatment: P = 0.0344; 
Interaction: P = 0.9504 
Ti: SD1 18.9 ± 18.2 22.0 ± 8.6 16.3 ± 8.7 14.0 ± 5.0 Genotype: P = 0.128; Treatment: P = 0.9128; 
Interaction: P = 0.432 
Ti: SD2 27.2 ± 14.0 28.1 ± 9.9 26.2 ± 21.1 21.0 ± 5.8 Genotype: P = 0.3048; Treatment: P = 0.579; 
Interaction: P = 0.4387 
Te: SD1 59.8 ± 34.7 59.1 ± 26.0 63. 7 ± 36.7 45.5 ± 17.6 Genotype: P = 0.5739; Treatment: P = 0.2777; 
Interaction: P = 0.3155 
Te: SD2 93.1 ± 41.0 79.5 ± 19.6 75.6 ± 49.9 60.9 ± 19.5 Genotype: P = 0.0888; Treatment: P = 0.1827; 
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Table 3. Diaphragm muscle contractile properties 
Group data (mean ± SD) for twitch contraction time (CT), twitch half-relaxation time (1/2 RT), 
maximum mechanical work (Wmax), maximum mechanical power (Pmax), peak shortening (Smax) 
and peak shortening velocity (Vmax) of diaphragm muscle from wild-type (WT; n = 7-10) and mdx (n 
= 8) mice injected subcutaneously with saline (0.9% w/v) or treatment [neutralizing interleukin-6 
receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. Data were 
statistically compared by two-way ANOVA followed by Bonferroni post hoc test. *mdx saline 
significantly different from corresponding WT saline value, P < 0.05.  
 WT mdx  
 Saline  
(n = 10) 
Treatment 
(n = 7) 
Saline 
(n = 8) 
Treatment (n = 
8) 
Two-way ANOVA 
CT (ms) 18.4 ± 2.8 19.4 ± 2.1 21.8 ± 
2.5* 
21.6 ± 2.5 Genotype P = 0.0038; Treatment P = 0.6824; 
Interaction P = 0.5097 
½ RT (ms) 23.5 ± 2.2 22.3 ± 2.6 23.9 ± 1.2 21.2 ± 6.4 Genotype P = 0.8129; Treatment P = 0.1353; 





1.5 ± 0.7 1.7 ± 1.0 0.5 ± 0.3* 1.0 ± 0.1 Genotype P = 0.0008; Treatment P = 0.0857; 





9.6 ± 3.9 11.9 ± 7.2 3.7 ± 2.9* 8.5 ± 2.5 Genotype P = 0.0047; Treatment P = 0.0276; 
Interaction P = 0.4137 
Smax (L/L
o






0.39 ± 0.02 Genotype P = 0.2412; Treatment P = 0.0998; 
Interaction P = 0.7863 
Vmax (L
o
/s) 4.5 ± 1.3 4.3 ± 1.7 3.1 ± 1.9 4.9 ± 0.9 Genotype P = 0.4947; Treatment P = 0.1557; 
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